The NIRD™ Series of Devices

We Will:

 

Save lives

Reduce exposure to CT-radiation

Save healthcare dollars

Promote effective use of CT's

 

We Can:

 

Detect bilateral bleeds

Scan the whole head

See as little as 2ml blood

Improve outcomes of TBI

NIRD™-HD (Hematoma Detector)

This device is designed to detect the presence of intracranial bleeds within 1 – 3 minutes. The underlying technology is designed to specifically see blood – abnormal volumes of blood that should not be present in a healthy and normal head. It is designed to help the person at the point of injury assess the severity of TBI, confirming the need for the rapid and immediate transport to a hospital with a CT scanner, so as to locate and image the bleed and expedite the delivery of treatment.  The NIRD™-HD is easy to use and provides audible and visual indication of a brain bleed.


Archeoptix received Health Canada approval for the NIRD™-HD on February 22, 2016.

  

NIRD™-HI (Hematoma Imager)

This device is a novel and unique extension of the NIRD™-HD, and is designed to image the extent of an intra-cranial bleed. That is, this device will now show you where the hematoma is located, as well as its extent. This device uses the same underlying technology as the NIRD™-HD, but we have added motion-tracking and shape-recovery algorithms so that we can image the bleed topographically (area) and tomographically (volume). This device is meant to be used as an adjunct to CT scans (the “gold standard”), and is not meant to be used in place of CT scans.

Concussion

NIRD™-CI (Concussion Imager)

This is a unique and innovative technology that is intended to image concussions. Structural abnormalities associated with concussion were recently discovered and imaged using Positron Emission Tomography (PET), which is not practical, and certainly not portable. Due to insufficient resolution capabilities, CT and MRI cannot image these structures.

We have proven that we can image these structures with our technology, and by monitoring them, we can determine when they are no longer present.  This is key to the development of this device as our ultimate goal is to provide a quantifiable and objective test for the safe return to play/work/active duty, so as to reduce the risks (and dangers) associated with “Second Impact Syndrome” (SIS). Identifying concussion is only part of the story - knowing when to safely come back is equally as important, if not more important.